New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 11, 2014
10:03 EDTSWY, XOMA, PANW, NLNK, BIGOptions with decreasing implied volatility: NLNK XOMA BIG PANW SWY
News For NLNK;XOMA;BIG;PANW;SWY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 25, 2014
06:36 EDTPANWPalo Alto strong Q1 likely priced into shares, says Citigroup
Subscribe for More Information
November 24, 2014
18:17 EDTPANWOn The Fly: After Hours Movers
Subscribe for More Information
16:05 EDTPANWPalo Alto sees Q2 EPS 16c-17c, consensus 16c
Subscribe for More Information
16:05 EDTPANWPalo Alto reports Q1 EPS 15c, consensus 12c
Reports Q1 revenue $192.3M, consensus $181.73M.
15:20 EDTPANWNotable companies reporting after market close
Subscribe for More Information
14:49 EDTPANWPalo Alto Networks November 112 straddle priced for 6.7% move
Subscribe for More Information
10:55 EDTNLNKNewLink Genetics January and April volatility elevated
Subscribe for More Information
07:33 EDTNLNKMerck, NewLink enter licensing, collaboration agreement for Ebola vaccine
Merck (MRK) and NewLink Genetics (NLNK) announced that they have entered into an exclusive worldwide license agreement to research, develop, manufacture, and distribute NewLink's investigational rVSV-EBOV vaccine candidate. Under the terms of the agreement, Merck will be granted the exclusive rights to the rVSV-EBOV vaccine candidate as well as any follow-on products. The vaccine candidate is under an exclusive licensing arrangement with a wholly-owned subsidiary of NewLink Genetics. Under these license arrangements, the PHAC retains non-commercial rights pertaining to the vaccine candidate. Phase I clinical trials of the rVSV-EBOV vaccine are now underway at the Walter Reed Army Institute of Research and the NIAID at the NIH. Additional Phase I studies are underway or planned to begin in the near future at clinical research centers in Switzerland, Germany, Kenya, and Gabon in a World Health Organization-coordinated effort, and in Canada by the Canadian Immunization Research Network.
07:31 EDTNLNKMerck, NewLink Genetics enter into agreement for investigational Ebola vaccine
Subscribe for More Information
07:03 EDTPANWPalo Alto volatility elevated into Q1 and outlook
Subscribe for More Information
November 21, 2014
14:49 EDTPANWPalo Alto volatility elevated into Q1 and outlook
Palo Alto November weekly call option implied volatility is at 65, December is at 51, January is at 46, March is at 42; compared to its 26-week average of 52 according to Track Data, suggesting large near term price movement into the expected release of Q1 results on November 24.
08:19 EDTPANWPalo Alto results, guidance should beat expectations, says JMP Securities
JMP Securities expects Palo Alto's Q1 results and its guidance to beat consensus estimates. The firm thinks the company benefited from strong demand for next generation security technologies as well as share gains from legacy firewall vendors.
November 20, 2014
15:14 EDTNLNKTraveler returned from Mali being tested for Ebola in NYC, Daily News reports
Subscribe for More Information
08:00 EDTPANWPalo Alto Q1 business looks to be beating consensus, says Oppenheimer
Oppenheimer believes that its checks suggest that Palo Alto's business is tracking ahead of consensus estimates. The firm thinks the company has continued strength across all core products and geographies. It raised its price target on the name to $120 from $115 and keeps an Outperform rating.
November 19, 2014
09:01 EDTPANWBig data for security could reach $4B-$5B, says FBR Capital
Subscribe for More Information
November 18, 2014
10:15 EDTPANWPalo Alto price target raised to $120 from $110 at Imperial Capital
Imperial Capital raised its price target for Palo Alto Networks to $120 ahead of the company's Q1 results and keeps an Outperform rating on the stock. The firm says Palo is "emerging as a dominant player in security."
07:21 EDTPANWPalo Alto price target raised to $125 from $105 at Stephens
Stephens said it expects Palo Alto's Q1 results to beat consensus estimates, citing the firm's positive channel checks. The firm, which believes Palo Alto is continuing to take market share, raised its price target on the stock to $125 from $105 and maintains its Overweight rating on the shares.
November 17, 2014
08:44 EDTNLNKNebraska Medical announces death of third Ebola patient
The Nebraska Medical Center said via Twitter, "We are sorry to announce that the 3rd Ebola patient, Dr. Martin Salia, has passed away as a result of the advanced symptoms of the disease." Drug companies that are working on experimental Ebola vaccines or treatments include Peregrine (PPHM), Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Some companies that offer protective clothing and waste disposal include Lakeland Industries (LAKE), Alpha Pro Tech (APT) and Sharps Compliance (SMED).
06:48 EDTPANWState Department hacked, NY Times reports
Subscribe for More Information
November 16, 2014
19:34 EDTPANWFinancial services firms plan $2B increase in cybersecurity spending, WSJ says
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use